LakeShore Biopharma Completes Going-Private Transaction at $0.066 Per Share
Summary
LakeShore Biopharma has completed its going-private merger, with shareholders receiving $0.066 per share. The company will now cease to be publicly traded and will delist from OTC Markets.
Key Events
-
Merger Completed
LakeShore Biopharma has completed its merger with Oceanpine Merger Sub Inc., becoming a wholly-owned subsidiary of Oceanpine Skyline Inc.
-
Cash Payout to Shareholders
Each ordinary share issued and outstanding immediately prior to the merger's effective time was cancelled in exchange for US$0.066 in cash per share.
-
Cessation of Public Trading
The company will cease to be publicly traded and intends to suspend its reporting obligations by filing a Form 15 with the SEC. Its trading symbols are expected to be removed from the OTC Pink tier.
-
Finalizes Prior Agreement
This completion follows the amended merger agreement from April 29, 2026, which drastically reduced the per-share consideration from an initial US$0.90 to US$0.066.
Analysis
This filing announces the definitive completion of LakeShore Biopharma's going-private merger. As a result, the company will cease to be publicly traded, and its shares will be delisted from the OTC Markets. Shareholders will receive a cash consideration of $0.066 per share, finalizing a process that saw the initial merger price significantly reduced. This marks the end of public investment in the company.
At the time of this filing, LSBCF was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $0.03 to $2.80. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.